Potential Treatment Of iBD Indicated
Result of research, conducted by University of Alabama – Birmingham researcher and professor of medicine, Dr. Charles O. Elson M.D., support a potential immunotherapy that could prevent or mitigate IBD.
Using a process called cell activation with concomitant metabolic checkpoint inhibition, or CAMCI, Dr. Elson believes that this “approach could be tailored to individuals (. . .) as a personalized immunotherapy.” Through parenteral use of CAMCI in mice, the research successfully targeted microbiota flagellin-specific CD4-positive T cells, leading to significant antigen-specific CD4-positive T cell death, impaired development and impaired reactivation of CD4-positive memory responses, and substantial induction of a CD4-positive Treg cell response.
Read more about this new discovery at https://tinyurl.com/yx99njkk